Eutropin Inj. (Human Growth Hormone)

Indication: Short stature due to inadequate secretion of endogenous growth hormone in children (Pediatric Growth Hormone Deficiency, PGHD),Turner Syndrome (TS), Chronic Renal Insufficiency (CRI), in children bor Small for Gestational Age (SGA), Idiopathic Short Stature (ISS); Replacement therapy in adults with GH deficiency of either childhood - or adult-onset etiology

Dosage and Administration: PGHD: 0.5-0.6 IU/kg/week or 12 IU/m2 body surface area/weak divided into 3 to 6 SC injections; TS: 1 IU/kg/week is given by SC or IM divided into 6-7 injections; CRI: 0.15 IU/kg/day is given by SC Injection; SGA: 0.48 mg/kg/week is given divided into 6-7 SC Injections; ISS: 0.37 mg/kg/week is given divided Into 6 SC Injections; Replacement therapy in adult GHD: The recommended dosage at the start of therapy is 0.125 IU (0.04 mg)/kg/week, divided into 6-7 injections.

The dose may be increased according to individual patient requirements to a maximum of 0.25 IU (0.08 mg/kg/week

Presentation: 4 IU/vial x 1, 5, 10 vials/pack, 1,5 IU/vial x 1 vial/pack: 36 IU/pen/pack Storage Condition: Store in hermetic container at 2-8°C